XORTX Therapeutics has refiled its Management's Discussion and Analysis (MD&A) for both fiscal year 2023 and Q2 2024 following a review by the Alberta Securities Commission. The amended year-end 2023 MD&A now includes a complete definition of Disclosure Controls and Procedures under Internal Controls Over Financial Reporting section.The Q2 2024 MD&A amendments feature additional details on funding allocation for product candidates and estimated costs in the Outlook section. Both documents, restated as of September 12, 2024, maintain their original content except for these specific updates and should be read alongside the corresponding financial statements.XORTX continues to advance two main clinical programs: XRx-008 for ADPKD and XRx-101 for acute kidney injury related to COVID-19 infection. The company also has XRx-225, a pre-clinical program for Type 2 Diabetic Nephropathy, focusing on treatments that target abnormal purine metabolism and xanthine oxidase to reduce uric acid production.

XORTX Therapeutics has refiled its Management's Discussion and Analysis (MD&A) for both fiscal year 2023 and Q2 2024 following a review by the Alberta Securities Commission. The amended year-end 2023 MD&A now includes a complete definition of Disclosure Controls and Procedures under Internal Controls Over Financial Reporting section.The Q2 2024 MD&A amendments feature additional details on funding allocation for product candidates and estimated costs in the Outlook section. Both documents, restated as of September 12, 2024, maintain their original content except for these specific updates and should be read alongside the corresponding financial statements.XORTX continues to advance two main clinical programs: XRx-008 for ADPKD and XRx-101 for acute kidney injury related to COVID-19 infection. The company also has XRx-225, a pre-clinical program for Type 2 Diabetic Nephropathy, focusing on treatments that target abnormal purine metabolism and xanthine oxidase to reduce uric acid production.